Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on February 2, 2022, covering events that occurred on January 27, 2022. The filing primarily addresses Item 5.02 regarding the departure of directors or certain officers, specifically focusing on the appointment of certain officers and their compensatory arrangements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a disclosure of executive compensation awards rather than a financial results report.
Material Changes and Executive Compensation
Effective January 27, 2022, the Company granted significant long-term incentive awards to two key executives in recognition of their 2021 contributions:
- Marc Benathen (Chief Financial Officer):
- 75,000 Restricted Stock Units (RSUs): 25,000 vesting on the grant date, with the remainder vesting on the first and second anniversaries.
- 250,000 Performance Share Units (PSUs).
- Rationale: Contributions to financial infrastructure, investor relations, compliance, and leading the 2021 preferred share offering.
- Eric Yecies (General Counsel and Chief Compliance Officer):
- 37,500 Restricted Stock Units (RSUs): 12,500 vesting on the grant date, with the remainder vesting on the first and second anniversaries.
- 105,000 Performance Share Units (PSUs).
- Rationale: Contributions to compliance, legal infrastructure, and the formation of the affiliated network of medical professional corporations.
Terms, Risks, and Contingencies
Vesting Conditions: The Performance Share Units vest upon the achievement of specific milestones over a five-year performance period:
- Key revenue and EBITDA milestones.
- Share price appreciation milestones.
Forfeiture and Change of Control: Unvested awards are forfeited if the executive departs for any reason. However, in the event of a Change of Control (as defined in the exhibits), 100% of the awards vest immediately.
Documentation: The awards are governed by amendments to the executives' employment agreements, filed as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Review Exhibit 10.1 and Exhibit 10.2 for the complete terms of the employment amendments.
- Verify the specific definitions of the "key revenue and EBITDA milestones" and "share price appreciation milestones" required for PSU vesting.
- Confirm the exact vesting schedule dates for the RSUs beyond the grant date.
- Assess the potential dilution impact of the 350,000 total RSUs and 355,000 total PSUs granted.